Synovo Gmbh

Other

Convatec Technologies, Inc.

Takeda Gmbh

Merckle Gmbh

C-a-i-r Biosciences Gmbh

Katairo Gmbh

Pharos Pharmaceuticals Inc.

Diosamine Development Corporation

Qualizyme Diagnostics Gmbh and Co Kg

Michael W Burnet

Jan-Hinrich Guse

Hans-Jurgen Gutke

Mary Eggers

Gene Kim

Christiane Bauerlein

Michael Wolff

Albert Beck

Georgia Tsotsou

Irina Droste-Borel

Laurence Barker

Ulrike Hahn

Jörg Senn-Bilfinger

David Parsons

Lucy Louisa Ballamy

Ernst Sturm

Guido Hanauer

Frank Totzke

Philip Godfrey Bowler

Sarah Wroe

Michael Kubbutat

Nikolas Pietrzik

Christiane Baeuerlein

Christoph Schaechtele

Daniel Gary Metcalf

Michael Peter Seed

Daniel Luschnig

Jan Ehlert

Ulrich Schraermeyer

Maximilian Busch

Moussa Khobzaoui

Simona Margutti

Bassam Abu Thaher

Thomas Meindl

Simon Strass

Jade Steven

Hans Hurgen Gutke

Andrea Heinzle

Eva Sigi

Clemens Gamerith

Stefan Laufer

Pierre Koch

Jeannette Reichert

Kattie Luyten

Provided herein are microbial infection indicator devices, including dressing with indicators, standalone indicator inserts or disks that can be freely placed at a wound site or dressing, and applications thereof for displaying a visible or detectable signal to a user upon detection of an analyte or biomarker indicative of an infection, such as a color change.

Detecting microbial infections in wounds

Lysosomally accumulated substances that release a nitroxy group, or a short chain fatty acid or a product of anaerobic metabolism or a thiol or a sulfide often from an ester or similar labile linkage have anti-inflammatory, anti-cancer and anti-bacterial activity. They are useful in treating infectious, inflammatory and malignant disease.

Anti-infective and anti-inflammatory compounds

A method for selecting a compound or a composition suitable for treating lipofuscin associated diseases in a patient, the method including the steps of determining a reactivity factor, determining a targeting factor that allows an uptake into a cell and a provides a targeting of lipofuscin, and selecting a compound or a composition or combining compounds to obtain a compound or composition that comprises a reactivity factor and an targeting factor.

Methods for the determination of compounds or compositions for the treatment of lipofuscin related diseases and compounds or compositions

A method of treating cancer in which a compound that inhibits the expression, production or release of IL-10 by immune cells is combined with a compound that stimulates the production of IL-12 when given in combination with, or in the presence of TNFa. Said method is effective when provided in addition to standard therapies, notably chemotherapy using cytotoxic drugs and other forms of immune therapy including therapeutic vaccines.

Kinase modulators for the treatment of cancer

The invention provides novel compounds and compositions and methods for making and using the compounds and compositions. In particular, the use of organic acid salts promotes solubility. These more soluble forms are suitable for use in various diseases, notably diseases of lung, muscle, metabolism and eyesight.

Anti-inflammatory macrolides

Compounds of the substituted pyrazole class as treatments for cancer are reported. A method of treating cancer in which a compound that inhibits the activity of receptor kinases. Said method is effective and can be provided in addition to standard therapies, notably chemotherapy using cytotoxic drugs and other forms of immune therapy including therapeutic vaccines.

The invention provides novel compounds and compositions and methods for making and using the compounds and compositions. 

The present invention is directed to sulphated compounds comprising at least one glycosidic amine group, and polysaccharide, oligosaccharide, peptide and protein derivatives comprising such compounds, and mixtures thereof. The present invention is also directed to methods of synthesizing such compounds. Such compounds may bind to a range of proteins, find application in methods of modifying, or testing for a modification in the level of a cytokine in vivo, ex vivo or in vitro, and find application in the treatment and/or prevention of inflammation, an inflammatory disorder, a proliferative disorder, an immune disorder, an angiogenesis-dependent disorder, a sensitivity disorder, an adverse endocrine reaction, a degenerative disorder, wound healing, depression, and other diseases and disorders.

Compounds

The invention features novel macrocyclic compounds, methods of making the compounds, pharmaceutical compositions including the compounds, and methods of treatment using the compounds.

Macrocyclic compounds pounds and methods of use thereof

This invention features a method of identifying a compound useful for enhancing efficacy of a therapeutic agent. The method includes incubating a compound in blood cells; separating immune cells from erythrocytic cells; and determining the ratio of the concentration of the compound in the immune cells to the concentration of the compound in the erythrocytic cells; wherein the compound comprises a transportophore and a therapeutic agent, in which the transportophore is covalently bonded to the therapeutic agent via a bond or a linker.

Method of identifying improved conjugates of biologically active compounds

The invention relates to 2-thio-substituted imidazole derivatives of the Formula I, and to methods of use thereof.

2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors

Macrocyclic compounds and methods of use thereof

This invention features a compound of the following formula:T-(-L-C), T is a transportophore, L is a bond or a linker having a molecular weight up to 240 dalton, C is a non-antibiotic therapeutic agent, and m is 1, 2, 3, 4, 5, 6, 7, or 8, in which the transportophore has an immune selectivity ratio of at least 2, the transportophore is covalently bonded to the non-antibiotic therapeutic agent via the bond or the linker, and the compound has an immune selectivity ratio of at least 2.

Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof

This invention features a compound of the following formula: wherein T is a transportophore, L is a bond or linker, and C is an antibiotic therapeutic agent, the transportophore is covalently bonded to the antibiotic therapeutic agent via the bond or the linker, and the transportophore is an azithromycin derivative or crown ether derivative.

Antibiotic conjugates

Growing community of inventors

Tübingen, Germany

Michael W Burnet